Cannabis for epilepsy
Pro Research Analysisby 
Searched over 200M research papers
Cannabis for Epilepsy: A Comprehensive Review
Introduction to Cannabis and Epilepsy
Epilepsy is a neurological disorder characterized by recurrent seizures, affecting millions worldwide. Traditional antiepileptic drugs (AEDs) are effective for many, but approximately 30% of patients have treatment-resistant epilepsy (TRE)2. This has led to growing interest in alternative treatments, including cannabis and its derivatives.
Cannabidiol (CBD) and Its Mechanisms
Cannabidiol (CBD), a non-psychoactive component of cannabis, has shown promise as an anticonvulsant. Unlike Δ-9-tetrahydrocannabinol (THC), CBD does not produce euphoric effects and has a low affinity for cannabinoid receptors CB1 and CB2. Its anticonvulsant properties are thought to be mediated through various mechanisms, including modulation of ion channels, neurotransmitter transporters, and multiple receptors2 5 6.
Clinical Efficacy of CBD in Epilepsy
Pediatric Epilepsy
Several studies have focused on the use of CBD in pediatric epilepsy, particularly in treatment-resistant forms like Dravet syndrome and Lennox-Gastaut syndrome. Randomized controlled trials (RCTs) have demonstrated that CBD significantly reduces seizure frequency compared to placebo4 7 8. For instance, a meta-analysis of four trials involving 550 patients showed that CBD reduced seizure frequency by approximately 20% more than placebo7. Additionally, observational studies have reported that nearly half of the patients experienced a 50% or greater reduction in seizures8.
Adult Epilepsy
While most research has focused on pediatric populations, there is evidence suggesting that adults with epilepsy also benefit from CBD. Studies have shown that adults use non-medical cannabis (NMC) for various reasons, including seizure control, with many reporting perceived benefits1. However, the data is more heterogeneous and less robust compared to pediatric studies.
Safety and Adverse Effects
CBD is generally well-tolerated, but it is not without side effects. Common adverse events include somnolence, decreased appetite, diarrhea, and elevated liver enzymes5 7. The risk of adverse events is higher when CBD is used in conjunction with other AEDs, such as clobazam and valproate, due to potential drug-drug interactions5.
Whole-Plant Cannabis vs. Purified CBD
There is ongoing debate about the efficacy of whole-plant cannabis versus purified CBD. Some argue that whole-plant extracts, which contain a variety of cannabinoids and terpenes, may offer additional therapeutic benefits through the "entourage effect"9. However, whole-plant cannabis also carries the risk of psychoactive effects and variability in composition, making it less predictable and potentially less safe than purified CBD products6 9.
Conclusion
Cannabis, particularly CBD, shows significant promise as an adjunctive treatment for epilepsy, especially in treatment-resistant cases. While the evidence is strongest for pediatric epilepsy, there is also potential for adult patients. However, more rigorous clinical trials are needed to fully understand the mechanisms, efficacy, and safety of cannabis-based treatments. As research continues, it is crucial for clinicians, patients, and policymakers to stay informed about the evolving landscape of cannabis in epilepsy treatment.
Sources and full results
Most relevant research papers on this topic
Use of non-medical cannabis in epilepsy: A scoping review
Non-medical cannabis use in people with epilepsy is sparse and heterogeneous, with most believing it aids in seizure control, but more research is needed to fill knowledge gaps.
Systematic ReviewThe Pharmacological Basis of Cannabis Therapy for Epilepsy
Cannabis therapy, primarily CBD, shows potential as an alternative treatment for refractory epilepsy, but the exact mechanisms underlying its anticonvulsant efficacy remain unclear.
Highly CitedCannabis for pediatric epilepsy: protocol for a living systematic review
Cannabis use in children with treatment-resistant epilepsy may provide benefits and harms, but more research is needed to inform decisions about its use.
Systematic Review
Very Rigorous JournalCannabis based drug shows promise in children with resistant epilepsy
Cannabidiol, a cannabis-based drug, shows promising results in treating Dravet syndrome in children unresponsive to existing drugs.
RCTVery Rigorous JournalCannabis for the Treatment of Epilepsy: an Update
CBD, a non-psychoactive component of cannabis, shows potential in reducing seizure frequency in patients with various types of epilepsy, but may interact with certain medications.
Literature ReviewHighly CitedCannabinoids and Epilepsy
CBD shows promise as a well-tolerated, promising therapeutic for treating seizures in epilepsy, while whole-plant cannabis can both contribute to and reduce seizures.
Literature ReviewVery Rigorous JournalHighly CitedEfficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
CBD is an effective and safe adjunctive treatment for patients with epilepsy, reducing seizure frequency by at least 50% without causing significant withdrawal or adverse events.
Meta-AnalysisHighly CitedEvidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence
Cannabidiol (CBD) may reduce seizure frequency and improve quality of life in treatment-resistant epilepsy patients, but increased risk of adverse events and serious adverse events warrants further research.
Systematic Review
Rigorous JournalHighly CitedThe case for medical marijuana in epilepsy
Medical marijuana, specifically CBD:THC, can effectively reduce seizure frequency in children with epilepsy, potentially benefiting those with severe forms of the condition.
Case ReportHighly CitedCannabis-based products for pediatric epilepsy: An updated systematic review
Cannabidiol may reduce seizure frequency in children with drug-resistant epilepsy, but may increase the risk of gastrointestinal adverse events.
Systematic Review